{"pmid":32275256,"title":"Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.","text":["Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.","The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this <<vademecum>> with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.","Infez Med","Lombardy Section Italian Society Infectious And Tropical Diseases, -","32275256"],"abstract":["The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this <<vademecum>> with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19."],"journal":"Infez Med","authors":["Lombardy Section Italian Society Infectious And Tropical Diseases, -"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275256","week":"202015|Apr 06 - Apr 12","source":"PubMed","locations":["Italy","Lombardy","Lombardy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"e_drugs":["tocilizumab","Steroids"],"_version_":1663712077903036416,"score":7.9164424,"similar":[{"pmid":32234117,"title":"Potential short-term outcome of an uncontrolled COVID-19 epidemic in Lombardy, Italy, February to March 2020.","text":["Potential short-term outcome of an uncontrolled COVID-19 epidemic in Lombardy, Italy, February to March 2020.","Sustained coronavirus disease (COVID-19) transmission is ongoing in Italy, with 7,375 reported cases and 366 deaths by 8 March 2020. We provide a model-based evaluation of patient records from Lombardy, predicting the impact of an uncontrolled epidemic on the healthcare system. It has the potential to cause more than 250,039 (95% credible interval (CrI): 147,717-459,890) cases within 3 weeks, including 37,194 (95% CrI: 22,250-67,632) patients requiring intensive care. Aggressive containment strategies are required.","Euro Surveill","Guzzetta, Giorgio","Poletti, Piero","Ajelli, Marco","Trentini, Filippo","Marziano, Valentina","Cereda, Danilo","Tirani, Marcello","Diurno, Giulio","Bodina, Annalisa","Barone, Antonio","Crottogini, Lucia","Gramegna, Maria","Melegaro, Alessia","Merler, Stefano","32234117"],"abstract":["Sustained coronavirus disease (COVID-19) transmission is ongoing in Italy, with 7,375 reported cases and 366 deaths by 8 March 2020. We provide a model-based evaluation of patient records from Lombardy, predicting the impact of an uncontrolled epidemic on the healthcare system. It has the potential to cause more than 250,039 (95% credible interval (CrI): 147,717-459,890) cases within 3 weeks, including 37,194 (95% CrI: 22,250-67,632) patients requiring intensive care. Aggressive containment strategies are required."],"journal":"Euro Surveill","authors":["Guzzetta, Giorgio","Poletti, Piero","Ajelli, Marco","Trentini, Filippo","Marziano, Valentina","Cereda, Danilo","Tirani, Marcello","Diurno, Giulio","Bodina, Annalisa","Barone, Antonio","Crottogini, Lucia","Gramegna, Maria","Melegaro, Alessia","Merler, Stefano"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234117","week":"202014|Mar 30 - Apr 05","doi":"10.2807/1560-7917.ES.2020.25.12.2000293","keywords":["*COVID-19","*Coronavirus","*Lombardy outbreak","*SARS-CoV-2","*modelling"],"source":"PubMed","locations":["Italy","Lombardy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1663352135548403712,"score":180.50264},{"pmid":32272481,"title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","text":["Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.","Nature","Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao","32272481"],"abstract":["A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available."],"journal":"Nature","authors":["Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272481","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41586-020-2223-y","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663620083139739649,"score":171.16298},{"pmid":32275287,"title":"COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population.","text":["COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population.","Since the beginning of the COVID-19 epidemic in Italy, the Italian Government implemented several restrictive measures to contain the spread of the infection. Data shows that, among these measures, the lockdown implemented as of 9 March had a positive impact, in particular the central and southern regions of Italy, while other actions appeared to be less effective. When the true prevalence of a disease is unknown, it is possible estimate it, based on mortality data and the assumptive case-fatality rate of the disease. Given these assumptions, the estimated period-prevalence of COVID-19 in Italy varies from 0.35% in Sicity to 13.3% in Lombardy.","Acta Biomed","Signorelli, Carlo","Scognamiglio, Thea","Odone, Anna","32275287"],"abstract":["Since the beginning of the COVID-19 epidemic in Italy, the Italian Government implemented several restrictive measures to contain the spread of the infection. Data shows that, among these measures, the lockdown implemented as of 9 March had a positive impact, in particular the central and southern regions of Italy, while other actions appeared to be less effective. When the true prevalence of a disease is unknown, it is possible estimate it, based on mortality data and the assumptive case-fatality rate of the disease. Given these assumptions, the estimated period-prevalence of COVID-19 in Italy varies from 0.35% in Sicity to 13.3% in Lombardy."],"journal":"Acta Biomed","authors":["Signorelli, Carlo","Scognamiglio, Thea","Odone, Anna"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275287","week":"202015|Apr 06 - Apr 12","doi":"10.23750/abm.v91i3-S.9511","source":"PubMed","locations":["Italy","Italy","Italy","Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Epidemic Forecasting","Prevention"],"weight":1,"_version_":1663712077910376448,"score":166.79224},{"pmid":32273253,"title":"Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience.","text":["Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience.","OBJECTIVE: To discuss hospital pharmacists' role in providing pharmaceutical care for hospitalized patients with COVID-19 to promote patient care and management during the pandemic. METHOD: Based on the method of evidence-based pharmacy, clinical evidence of therapeutical drugs for COVID-19 were retrieved and summarized. Based on clinical experience Chinese hospital pharmacists gained from providing pharmaceutical care services during COVID-19 pandemic, taking COVID-19 hospitalized patients' needs into consideration, the methods and strategies hospital pharmacists shall use to provide pharmaceutical care were analyzed and summarized. RESULTS: Hospital pharmacists shall support pharmaceutical care services by participating in making evidence-based decisions for medication, monitoring and evaluation of medication safety and efficacy, providing strengthened care for special population and patients with combined underlying diseases, monitoring and management of convalescent plasma therapy, providing emotional counselling and psychological support, and providing scientific information about COVID-19 vaccines. CONCLUSION: The need of pharmaceutical care services in COVID-19 hospitalized patients during this pandemic was quite distinguished from the past. Hospital pharmacists shall join the collaborative multidisciplinary team to improve COVID-19 patients' outcome and reduce mortality, and to facilitate the pandemic control.","Res Social Adm Pharm","Song, Zaiwei","Hu, Yang","Zheng, Siqian","Yang, Li","Zhao, Rongsheng","32273253"],"abstract":["OBJECTIVE: To discuss hospital pharmacists' role in providing pharmaceutical care for hospitalized patients with COVID-19 to promote patient care and management during the pandemic. METHOD: Based on the method of evidence-based pharmacy, clinical evidence of therapeutical drugs for COVID-19 were retrieved and summarized. Based on clinical experience Chinese hospital pharmacists gained from providing pharmaceutical care services during COVID-19 pandemic, taking COVID-19 hospitalized patients' needs into consideration, the methods and strategies hospital pharmacists shall use to provide pharmaceutical care were analyzed and summarized. RESULTS: Hospital pharmacists shall support pharmaceutical care services by participating in making evidence-based decisions for medication, monitoring and evaluation of medication safety and efficacy, providing strengthened care for special population and patients with combined underlying diseases, monitoring and management of convalescent plasma therapy, providing emotional counselling and psychological support, and providing scientific information about COVID-19 vaccines. CONCLUSION: The need of pharmaceutical care services in COVID-19 hospitalized patients during this pandemic was quite distinguished from the past. Hospital pharmacists shall join the collaborative multidisciplinary team to improve COVID-19 patients' outcome and reduce mortality, and to facilitate the pandemic control."],"journal":"Res Social Adm Pharm","authors":["Song, Zaiwei","Hu, Yang","Zheng, Siqian","Yang, Li","Zhao, Rongsheng"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32273253","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.sapharm.2020.03.027","source":"PubMed","locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1663712077950222337,"score":159.83865},{"pmid":32207068,"title":"Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy.","text":["Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy.","Confronting the SARS-CoV-2 outbreak has allowed us to appreciate how efficiently highly-resourced settings can respond to crises. However even such settings are not prepared to deal with the situation, and lessons are only slowly being learnt. There is still an urgent need to accelerate protocols that lead to the implementation of rapid point-of-care diagnostic testing and effective antiviral therapies. In some high-risk populations, such as dialysis patients, where several individuals are treated at the same time in a limited space and overcrowded areas, our objective must be to ensure protection to patients, the healthcare team and the dialysis ward. The difficult Italian experience may help other countries to face the challenges. The experience of the Lombardy underlines the need for gathering and sharing our data to increase our knowledge and support common, initially experience-based, and as soon as possible evidence-based position to face this overwhelming crisis.","J Nephrol","Rombola, Giuseppe","Heidempergher, Marco","Pedrini, Luciano","Farina, Marco","Aucella, Filippo","Messa, Piergiorgio","Brunori, Giuliano","32207068"],"abstract":["Confronting the SARS-CoV-2 outbreak has allowed us to appreciate how efficiently highly-resourced settings can respond to crises. However even such settings are not prepared to deal with the situation, and lessons are only slowly being learnt. There is still an urgent need to accelerate protocols that lead to the implementation of rapid point-of-care diagnostic testing and effective antiviral therapies. In some high-risk populations, such as dialysis patients, where several individuals are treated at the same time in a limited space and overcrowded areas, our objective must be to ensure protection to patients, the healthcare team and the dialysis ward. The difficult Italian experience may help other countries to face the challenges. The experience of the Lombardy underlines the need for gathering and sharing our data to increase our knowledge and support common, initially experience-based, and as soon as possible evidence-based position to face this overwhelming crisis."],"journal":"J Nephrol","authors":["Rombola, Giuseppe","Heidempergher, Marco","Pedrini, Luciano","Farina, Marco","Aucella, Filippo","Messa, Piergiorgio","Brunori, Giuliano"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32207068","week":"202013|Mar 23 - Mar 29","doi":"10.1007/s40620-020-00727-y","link_erratum_in":"32232773","source":"PubMed","locations":["Lombardy","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1663352133733318657,"score":159.3865}]}